Dubai clinic launches June AMH testing offer to encourage earlier fertility check-ins
Orchid Fertility, a specialist reproductive clinic in Dubai Healthcare City, says it is running a complimentary testing programme throughout June 2026 aimed at helping women learn more about their fertility earlier than the point when they may already be trying to conceive.
The initiative centers on Anti-Müllerian Hormone, or AMH, blood testing. According to the clinic, AMH is used as an indicator of ovarian reserve, providing a snapshot of how many eggs may be available at a given time. The clinic also states that each free test is paired with a one-to-one consultation so results can be interpreted in the context of a patient’s broader health and goals.
While AMH testing is established in fertility care, the commercial element of a free offer highlights a recurring issue in healthcare access, awareness, and how patients engage with reproductive health services in the UAE.
What the AMH test measures, and why timing matters
AMH is measured through a blood draw. The clinic says the test helps estimate ovarian reserve, which is often used in clinical discussions about reproductive potential.
The campaign’s stated focus is on fertility awareness before a person is actively planning or attempting pregnancy. In practice, earlier testing can influence the questions patients ask, and the options they may consider. Orchid Fertility says the information may be used to guide planning for the near future, prompt discussions about fertility preservation such as egg freezing, or simply support patients who want clarity on their current numbers.
Clinicians generally emphasize that fertility measures should be interpreted individually. In this case, the clinic’s approach includes interpretation via specialist consultation, which it frames as a way to ensure patients understand what the results mean.
How the offer works
Orchid Fertility says the AMH testing is available throughout June 2026 and does not require a referral. Patients can book appointments directly through the clinic’s website.
The clinic also states that women who choose to act on their results will be able to discuss egg-freezing and fertility preservation options at special rates during the summer. However, the campaign is presented as primarily educational, with the clinic indicating that it is intended to provide information without pressure.
Institutional context in the UAE healthcare market
The announcement positions fertility testing within a broader trend in healthcare, where service providers seek to lower barriers to early screening and make specialist conversations more accessible. In the UAE, women’s health services have expanded in recent years, with increasing availability of specialized fertility clinics and diagnostic pathways.
At the same time, the structure of such campaigns matters. When testing is offered free, it can reduce cost-related hesitation for people who would otherwise delay appointments. Yet, the decision about how to use test results remains clinical and personal, not transactional. The consultation component is therefore central to how patients can translate a test into informed next steps.
Orchid Fertility says it has operated in the UAE for more than 10 years and highlights JCI and CAP accreditation. The clinic describes its model as multidisciplinary, including counselling and psychological support alongside fertility medicine, though the press release does not specify which parts would be offered within the free testing programme.
Implications for patients and policymakers
For patients, initiatives like this may help normalize reproductive health conversations earlier in the decision timeline. For healthcare systems, they can shift demand toward diagnostics and counselling rather than waiting until pregnancy attempts begin.
However, external campaigns also raise questions that patients may want to consider, such as how results are communicated, whether follow-up pathways are clearly explained, and what happens if further assessment is recommended.
In the absence of additional clinical detail in the announcement, prospective patients would likely need to confirm availability, consultation scope, and any next-step protocols during booking.
Bottom line
Orchid Fertility is offering complimentary AMH blood tests throughout June 2026 in Dubai Healthcare City, with specialist consultations intended to support earlier fertility awareness. The initiative reflects growing attention to reproductive decision-making timelines, while also underscoring the importance of clinical interpretation when test results are used to guide personal health choices.
